[message_box title=”Good News!” color=”red”]Belviq has been placed on the Tricare Formulary. It is the only Weight Loss Medication that has been included.[/message_box]
$0 for active duty
$13 for non-active mail order
$17 for non-active retail
Belviq (lorcaserin) affects chemicals in the brain that affect appetite.
Belviq is used together with diet and exercise to treat obesity
Belviq is sometimes used to treat obesity that may be related to diabetes, high cholesterol, or high blood pressure.
About BELVIQ (lorcaserin HCl)
For more information about BELVIQ, click here or for the full prescribing information or go to http://www.belviq.com/documents/Belviq_Prescribing_Information.pdf
BELVIQ Phase 3 Clinical Trial Program
The BELVIQ Phase 3 clinical trial program consisted of three double-blind, randomized, placebo-controlled trials: BLOOM (Behavioral modification and Lorcaserin forOverweight and Obesity Management), BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) and BLOOM–DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus). All three trials included a standardized program of diet, moderate exercise and behavioral counseling for both the placebo and BELVIQ groups.
BLOOM evaluated BELVIQ versus placebo over a two-year treatment period in 3,182 non-diabetic, obese (BMI of 30 to 45 kg/m2) adult patients (18 to 65 years old) with or without comorbid conditions and non-diabetic, overweight (BMI of 27 to 29.9 kg/m2) adult patients with at least one weight related comorbid condition.
BLOSSOM evaluated BELVIQ versus placebo over a one-year treatment period in 4,008 non-diabetic, obese (BMI of 30 to 45 kg/m2) adult patients (18 to 65 years old) with or without comorbid conditions and non-diabetic, overweight (BMI of 27 to 29.9 kg/m2) adult patients with at least one weight related comorbid condition.
BLOOM-DM evaluated BELVIQ versus placebo over a one-year treatment period in 604 obese (BMI of 30 to 45 kg/m2) and overweight (BMI of 27 to 29.9 kg/m2) adult patients (18 to 65 years old) with type 2 diabetes who were receiving oral antihyperglycemic agents.
BELVIQ is indicated to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:
- 30 kg/m2 or greater (obese), or
- 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)
Limitations of Use:
- The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations have not been established
- The effect of BELVIQ on cardiovascular morbidity and mortality has not been established
Important Safety Information
- Pregnancy: BELVIQ should not be taken during pregnancy or by women who are planning to become pregnant.
- Nursing: BELVIQ should not be taken while breastfeeding.
- Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions: BELVIQ and certain medicines for depression, migraine, the common cold, and mood, anxiety, psychotic or thought disorders or other medical problems may affect each other causing serious or life-threatening side effects. Patients should tell their doctor if they are taking medicines to treat any of these conditions such as: triptans, tricyclics, lithium, selective serotonin uptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or antipsychotics; linezolid, an antibiotic; tramadol; dextromethorphan, an over-the-counter medicine used to treat the common cold or cough; over-the-counter supplements such as tryptophan or St. John’s Wort. BELVIQ and these medicines should be discontinued immediately and symptomatic treatment measures should be initiated if patients taking BELVIQ and these other medicines experience any of the following: mental changes such as agitation, hallucinations, confusion, or other changes in mental status; coordination problems, uncontrolled muscle spasms, or muscle twitching (overactive reflexes); restlessness; racing or fast heartbeat, high or low blood pressure; sweating or fever; nausea, vomiting, or diarrhea; or muscle rigidity (stiff muscles).
- Valvular Heart Disease: Certain weight loss drugs have been associated with problems with the valves in the heart. Patients taking BELVIQ who have trouble breathing, swelling of the arms, legs, ankles, or feet, dizziness, fatigue, or weakness that will not go away, or fast or irregular heartbeat should call their doctor right away. Before taking BELVIQ, patients should tell their doctor if they have or had heart problems including congestive heart failure, or heart valve problems. Patients should not take BELVIQ in combination with drugs that have been associated with valvular heart disease (such as cabergoline). Patients who develop signs and symptoms of valvular heart disease while taking BELVIQ should be evaluated and discontinuation of BELVIQ should be considered by their doctor.
- Changes in Attention or Memory: Problems with thinking, sleepiness, confusion, and fatigue have been reported in patients taking BELVIQ.
- Patients taking BELVIQ should not drive a car or operate heavy machinery until they know how BELVIQ affects them.
- Mental Problems: Taking BELVIQ at higher than the recommended dose may cause psychiatric problems such as: hallucinations, feeling high or in a very good mood (euphoria), feelings of standing next to yourself or out of your body (disassociation). The recommended dose of 10 mg twice daily should not be exceeded. Patients should be monitored for the development or worsening of depression, suicidal thoughts or behaviors, and/or any changes in mood. BELVIQ should be discontinued if patients develop suicidal thoughts or behaviors.
- Low Blood Sugar (Hypoglycemia): Weight loss can cause low blood sugar in people with type 2 diabetes mellitus who are on medicines to treat it such as metformin, insulin, or sulfonylureas. Blood sugar levels should be monitored for patients who take BELVIQ. Changes to medicines may be needed if low blood sugar develops.
- Painful Erections (Priapism): If patients taking BELVIQ experience an erection lasting more than 4 hours, whether it is painful or not, they should stop using BELVIQ and call their doctor or go to the nearest emergency room right away. BELVIQ should be taken with caution by men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with a deformed penis. Patients should tell their doctor if they take medicines used to treat erectile dysfunction.
- Slow Heartbeat: BELVIQ may cause a slow heartbeat. Patients taking BELVIQ should tell their doctor if they have a history of a slow heartbeat or heart block.
- Decreases in Blood Cell Count: BELVIQ may cause decreases in red or white blood cell count. A doctor may do tests to check a patient’s blood cell count during treatment with BELVIQ.
- Increase in Prolactin: BELVIQ may increase the amount of a hormone the body makes, called prolactin. Patients taking BELVIQ should tell their doctor if their breasts begin to make milk or have a milky discharge or if their breasts begin to increase in size.
- Increased Pressure in the Arteries of the Lung (Pulmonary Hypertension): Certain weight loss drugs have been associated with the rare but life-threatening side effect of increased pressure in the arteries of the lung. It is unknown if BELVIQ increases the risk for this condition.
- Most Common Adverse Reactions In Non-Diabetic Patients: Headache, dizziness, fatigue, nausea, dry mouth, and constipation.
- Most Common Adverse Reactions in Diabetic Patients: Hypoglycemia, headache, back pain, cough, and fatigue.
- Response to BELVIQ should be evaluated at 12 weeks of treatment to determine if therapy should be discontinued.